Immunization, Vaccines and Biologicals

SAGE Working Group on Hepatitis E (October 2013 to December 2014)

Terms of Reference

The Working Group will be asked to review the evidence with respect to the following questions/issues and to propose recommendations for review by SAGE. This will lead to the publication of a WHO vaccine position paper on the use of hepatitis E. The target date of the publication of the position paper is early 2015.

  • Review data regarding the global incidence and burden of disease caused by hepatitis E virus infection.
  • Review issues related to hepatitis E surveillance
  • Review existing data on the safety, immunogenicity, efficacy, and cost-effectiveness of the licensed hepatitis E vaccine
  • Review the hepatitis E vaccine pipeline.
  • Identify potential indications and uses for the hepatitis E vaccine in the context of other hepatitis E preventive, control and treatment strategies/tools
  • Provide draft recommendations on the potential use of hepatitis E vaccine.
  • To summarize existing evidence on the burden of hepatitis E and on the safety, immunogenicity, efficacy, and cost-effectiveness of the licensed hepatitis E vaccine.
  • To provide SAGE with summaries and analyses needed to support its discussion and recommendation process.

Composition

SAGE Members

  • Narendra Arora, Chair of the Working Group, Executive director, International Clinical Epidemiology Network, India
  • Xiaofeng Liang, Deputy Director General, Chinese Center for Disease Control, China

Experts

  • Emily Gurly, Associate Director for Science and Head of Outbreak and Surveillance Research Group, Center for Communicable Diseases, International Centre for Diarrheal Diseases Research, Bangladesh
  • Rakesh Aggarwal, Professor Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India
  • David Rein, Principal Research Scientist, NORC at the University of Chicago, Public Health Research Department, USA
  • Sally Baylis, Senior scientist and quality assessor, Division of Virology, Paul-Ehrlich-Institut, Germany
  • Eyasu Teshale, Centers for Disease Control and Prevention, Division of Viral Hepatitis Epidemiology and Surveillance Branch, USA
  • Nilsa de Deus, Head of Research Department National Institute of Health, Minister of Health, Mozambique
  • Samreen Ijaz, Clinical Scientist, R&D lead for blood borne infections, Blood Borne Virus Unit, Virus Reference Department, Public Health England, UK
  • Rana Jawad Asghar, Resident Advisor, Field Epidemiology and Laboratory Training Programme, Pakistan

WHO Secretariat

  • Hande Harmanci

DECLARATION OF INTERESTS

All 10 members of the Working Group on Hepatitis E vaccines provided their declaration of interest form. One member reported relevant interests. It was concluded that all members could take part in full in all discussions and decision-making processes.

Samreen Ijaz

  • Her institution receives research support from National Health Service Blood and Transplant for Hepatitis E related projects. This interest was assessed as non-personal, specific and financially significant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

Last updated: 18 December 2014

Share